GeNeuro SA (GNRO.PA)
EUR 0.06
(-4.72%)
EUR 0.06
(-4.72%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -293.8 Thousand EUR | -1.84% |
| 2022 | -288.5 Thousand EUR | 3.9% |
| 2021 | -300.2 Thousand EUR | 10.28% |
| 2020 | -334.6 Thousand EUR | 5.69% |
| 2019 | -354.8 Thousand EUR | -459.3% |
| 2018 | -63.43 Thousand EUR | -10.42% |
| 2017 | -57.45 Thousand EUR | -54.51% |
| 2016 | -37.18 Thousand EUR | -27.07% |
| 2015 | -29.26 Thousand EUR | -100.4% |
| 2014 | 7.3 Million EUR | 34523.22% |
| 2013 | 21.1 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q4 | -146.4 Thousand EUR | 0.0% |
| 2023 FY | -293.8 Thousand EUR | -1.84% |
| 2023 Q2 | -147.4 Thousand EUR | 0.0% |
| 2022 Q4 | -144.5 Thousand EUR | 0.0% |
| 2022 FY | -288.5 Thousand EUR | 3.9% |
| 2022 Q2 | -144 Thousand EUR | 0.0% |
| 2021 Q4 | -149.3 Thousand EUR | 0.0% |
| 2021 Q2 | -150.9 Thousand EUR | 0.0% |
| 2021 FY | -300.2 Thousand EUR | 10.28% |
| 2020 FY | -334.6 Thousand EUR | 5.69% |
| 2020 Q4 | -159.1 Thousand EUR | 0.0% |
| 2020 Q2 | -175.5 Thousand EUR | 0.0% |
| 2019 FY | -354.8 Thousand EUR | -459.3% |
| 2019 Q4 | -176.9 Thousand EUR | 0.0% |
| 2019 Q2 | -177.9 Thousand EUR | 0.0% |
| 2018 Q4 | 115.10 EUR | 0.0% |
| 2018 Q2 | 7348.00 EUR | 0.0% |
| 2018 FY | -63.43 Thousand EUR | -10.42% |
| 2017 Q4 | 11.66 Thousand EUR | 0.0% |
| 2017 Q2 | 3279.00 EUR | 0.0% |
| 2017 FY | -57.45 Thousand EUR | -54.51% |
| 2016 Q4 | 2483.10 EUR | 0.0% |
| 2016 FY | -37.18 Thousand EUR | -27.07% |
| 2016 Q2 | 3434.40 EUR | 0.0% |
| 2015 Q2 | 526.30 EUR | 0.0% |
| 2015 FY | -29.26 Thousand EUR | -100.4% |
| 2015 Q4 | 2013.00 EUR | 0.0% |
| 2014 Q3 | 1.82 Million EUR | 8738536.36% |
| 2014 Q1 | 1.82 Million EUR | 0.0% |
| 2014 Q2 | 20.90 EUR | -100.0% |
| 2014 FY | 7.3 Million EUR | 34523.22% |
| 2014 Q4 | 7284.60 EUR | -99.6% |
| 2013 FY | 21.1 Thousand EUR | 0.0% |
| 2013 Q1 | 5275.00 EUR | 0.0% |
| 2013 Q3 | 5275.00 EUR | 0.0% |
| 2013 Q4 | 1.82 Million EUR | 34523.22% |
| 2013 Q2 | 5275.00 EUR | 0.0% |
| 2012 Q4 | 5275.00 EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 147.54% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 107.506% |
| Adocia SA | 1.38 Million EUR | 121.213% |
| Aelis Farma SA | 12.35 Million EUR | 102.377% |
| Biophytis S.A. | -803 Thousand EUR | 63.412% |
| Advicenne S.A. | 1.42 Million EUR | 120.603% |
| genOway Société anonyme | 20.1 Million EUR | 101.462% |
| IntegraGen SA | 5.01 Million EUR | 105.855% |
| Medesis Pharma S.A. | -2.66 Million EUR | 88.975% |
| Neovacs S.A. | 29.31 Thousand EUR | 1102.251% |
| NFL Biosciences SA | -56.06 Thousand EUR | -424.044% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 113.647% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 79.299% |
| Sensorion SA | 3.78 Million EUR | 107.756% |
| Theranexus Société Anonyme | -4.63 Million EUR | 93.666% |
| TME Pharma N.V. | -127 Thousand EUR | -131.339% |
| Valbiotis SA | 2.66 Million EUR | 111.012% |
| TheraVet SA | -530.79 Thousand EUR | 44.649% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 123.189% |
| DBV Technologies S.A. | 4.15 Million EUR | 107.063% |
| Genfit S.A. | 28.22 Million EUR | 101.041% |
| Innate Pharma S.A. | -4.12 Million EUR | 92.871% |
| Inventiva S.A. | 17.5 Million EUR | 101.679% |
| MaaT Pharma SA | 1.65 Million EUR | 117.752% |
| MedinCell S.A. | 9.28 Million EUR | 103.163% |
| Nanobiotix S.A. | 36.2 Million EUR | 100.811% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 113.193% |
| Poxel S.A. | 1000.00 EUR | 29480.0% |
| GenSight Biologics S.A. | 3 Million EUR | 109.793% |
| Transgene SA | -28.4 Million EUR | 98.966% |
| Valneva SE | 52.83 Million EUR | 100.556% |